Literature DB >> 3018037

Phenotypic comparison of Pseudomonas aeruginosa strains isolated from a variety of clinical sites.

D E Woods, M S Schaffer, H R Rabin, G D Campbell, P A Sokol.   

Abstract

Pseudomonas aeruginosa elaborates a number of extracellular products which have been shown to play a role in the pathogenesis of disease caused by this organism. In this study, we showed that the host environment markedly affects the levels of exoproducts produced. We compared the phenotypes of a number of P. aeruginosa strains obtained from a variety of clinical sources, including burn wounds, skin wounds, urine, cystic fibrosis sputum, acute pneumonia sputum, and blood. The clinical isolates were examined quantitatively for levels of total protease, elastase, phospholipase C, exotoxin A, and exoenzyme S produced in vitro under defined conditions. The exoproduct levels varied significantly, depending on the site of isolation. Elevated levels of elastase were demonstrated in strains isolated from acute lung infections, phospholipase C levels were elevated in urinary tract and blood isolates, exotoxin A levels were elevated in blood isolates, and exoenzyme S levels were increased in acute pneumonia isolates. Isolates from cystic fibrosis sputum produced low amounts of virtually all of the tested exoproducts, particularly as compared with sputum isolates from acute P. aeruginosa lung infections.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3018037      PMCID: PMC268885          DOI: 10.1128/jcm.24.2.260-264.1986

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   11.677


  28 in total

1.  Pseudomonas aeruginosa exoenzyme S: an adenosine diphosphate ribosyltransferase distinct from toxin A.

Authors:  B H Iglewski; J Sadoff; M J Bjorn; E S Maxwell
Journal:  Proc Natl Acad Sci U S A       Date:  1978-07       Impact factor: 11.205

2.  Passive protection by antitoxin in experimental Pseudomonas aeruginosa burn infections.

Authors:  O R Pavlovskis; M Pollack; L T Callahan; B H Iglewski
Journal:  Infect Immun       Date:  1977-12       Impact factor: 3.441

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Antibodies to proteases and exotoxin A of Pseudomonas aeruginosa in patients with cystic fibrosis: Demonstration by radioimmunoassay.

Authors:  J D Klinger; D C Straus; C B Hilton; J A Bass
Journal:  J Infect Dis       Date:  1978-07       Impact factor: 5.226

5.  Enzymatically active peptide from the adenosine diphosphate-ribosylating toxin of Pseudomonas aeruginosa.

Authors:  D W Chung; R J Collier
Journal:  Infect Immun       Date:  1977-06       Impact factor: 3.441

6.  Microscopic characterization of rabbit lung damage produced by Pseudomonas aeruginosa proteases.

Authors:  L Gray; A Kreger
Journal:  Infect Immun       Date:  1979-01       Impact factor: 3.441

7.  Pseudomonas aeruginosa bacteremia: relationship of bacterial enzyme production and pyocine types with clinical prognosis in 100 patients.

Authors:  A L Baltch; P E Griffin; M Hammer
Journal:  J Lab Clin Med       Date:  1979-04

8.  PRODUCTION OF ELASTASE AND PROTEINASE BY PSEUDOMONAS AERUGINOSA.

Authors:  K MORIHARA
Journal:  J Bacteriol       Date:  1964-09       Impact factor: 3.490

9.  Role of exotoxin and protease as possible virulence factors in experimental infections with Pseudomonas aeruginosa.

Authors:  K Snell; I A Holder; S A Leppla; C B Saelinger
Journal:  Infect Immun       Date:  1978-03       Impact factor: 3.441

10.  Incidence of exotoxin production by Pseudomonas species.

Authors:  M J Bjorn; M L Vasil; J C Sadoff; B H Iglewski
Journal:  Infect Immun       Date:  1977-04       Impact factor: 3.441

View more
  41 in total

1.  Elastase deficiency phenotype of Pseudomonas aeruginosa canine otitis externa isolates.

Authors:  S R Petermann; C Doetkott; L Rust
Journal:  Clin Diagn Lab Immunol       Date:  2001-05

2.  O-antigen serotypes and type III secretory toxins in clinical isolates of Pseudomonas aeruginosa.

Authors:  Karine Faure; David Shimabukuro; Temitayo Ajayi; Leonard R Allmond; Teiji Sawa; Jeanine P Wiener-Kronish
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

Review 3.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

4.  Virulence determinants in Pseudomonas aeruginosa strains from urinary tract infections.

Authors:  P Visca; F Chiarini; A Mansi; C Vetriani; L Serino; N Orsi
Journal:  Epidemiol Infect       Date:  1992-04       Impact factor: 2.451

5.  Extracellular enzymes of fecal strains of Pseudomonas aeruginosa.

Authors:  C Marne; A Vindel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-04       Impact factor: 3.267

6.  Epidemic population structure of Pseudomonas aeruginosa: evidence for a clone that is pathogenic to the eye and that has a distinct combination of virulence factors.

Authors:  J A Lomholt; K Poulsen; M Kilian
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

7.  Pyoverdine and proteases affect the response of Pseudomonas aeruginosa to gallium in human serum.

Authors:  Carlo Bonchi; Emanuela Frangipani; Francesco Imperi; Paolo Visca
Journal:  Antimicrob Agents Chemother       Date:  2015-07-06       Impact factor: 5.191

8.  Surface expression of ferripyochelin-binding protein is required for virulence of Pseudomonas aeruginosa.

Authors:  P A Sokol
Journal:  Infect Immun       Date:  1987-09       Impact factor: 3.441

9.  Native valve endocarditis caused by an organism resembling Corynebacterium striatum.

Authors:  S M Markowitz; P E Coudron
Journal:  J Clin Microbiol       Date:  1990-01       Impact factor: 5.948

10.  Role of alginate in infection with mucoid Pseudomonas aeruginosa in cystic fibrosis.

Authors:  S S Pedersen; N Høiby; F Espersen; C Koch
Journal:  Thorax       Date:  1992-01       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.